Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. April 2026 06:39 ET | Quelle: Research and Markets

Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Drugs Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035" report has been added to ResearchAndMarkets.com's...
17. April 2026 15:00 ET | Quelle: Asgard Therapeutics

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

Asgard Therapeutics to present a poster on its lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026.
10. April 2026 08:15 ET | Quelle: BCC Research LLC

Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate

Report provides in-depth insights into technological developments, pipeline trends, and global opportunities shaping the future of bispecific antibodies.
09. April 2026 03:30 ET | Quelle: Kainova Therapeutics

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

Kainova Therapeutics has dosed the first European patient in its Phase I/II DOMISOL trial of DT-7012, advancing its Treg-depleting immunotherapy program.
02. April 2026 11:34 ET | Quelle: Research and Markets

Throat Cancer Market Trends and Breakthroughs Through 2026-2030 & 2035 Driven by Precision Oncology

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Throat Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The throat cancer market has exhibited significant growth...
10. März 2026 04:30 ET | Quelle: Kainova Therapeutics

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.
03. Februar 2026 07:51 ET | Quelle: Research and Markets

Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market 2025-2029 - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant...
10. Dezember 2025 09:15 ET | Quelle: Research and Markets

China Leads Therapeutic Access with 74 Approved Immuno-Oncology Agents

Dublin, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Immuno-oncology (2025)" has been added to ResearchAndMarkets.com's offering. The latest report delves into the dynamic...
07. November 2025 17:10 ET | Quelle: Evaxion

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation of unprecedented two-year clinical efficacy data from the...
30. Oktober 2025 09:00 ET | Quelle: Nouscom Srl

Nouscom to Present New Positive Phase 1b/2 Clinical and Translational Data on NOUS-209 Immunogenicity and Cancer Interception Potential in Lynch Syndrome Carriers at SITC 2025

Lynch Syndrome (LS) is a common hereditary condition that greatly increases lifetime risk of colorectal, endometrial, urothelial and other cancersNOUS-209 is an off-the-shelf immunotherapy...

Nächste Seite